Hit – Although Gil Cisneros says he supports lowering prescription drug prices, records show he owned up to one million dollars in pharmaceutical and biotechnology companies’ stock, and his foundation owned stock in companies that increased the price on an arthritis medication by more than 1,6000 percent, and another raised the price of insulin by nearly seven hundred percent. Backup: Gil Cisneros supported legislation, H.R.3, the Lower Drug Costs Now Act: • According to his press release, Cisneros is a staunch supporter of lowering prescription drug

prices. “Today, Representative Gilbert R. Cisneros, Jr. (CA-39) released the following statement after H.R. 3, the Lower Drug Costs Now Act, passed the House. The Act will reduce prescription drug costs for millions of Americans. Rep. Cisneros has been a staunch advocate for lowering prescription drug costs and reducing healthcare costs for his constituents.”

• Gil Cisneros voted for H.R.3. (H.R. 3, Roll Call #682, Passed 230-192: R 2-191, D 2228-0, 12/12/19) Gil Cisneros supported lowering the costs of prescription drug prices:

• Gil Cisneros supports the government lowering prescription drug prices by negotiating with those companies. “We need to work to stabilize insurance markets and have the government directly negotiate drug prices with pharmaceutical companies to bring costs down.”

(Healthcare For All, Gil Cisneros For Congress, accessed 04/09/2019)

Gil Cisneros is part of the Freshman Working Group On Addiction:

• Cisneros joined the Freshman Working Group On Addiction to fight against substance abuse and the opioid epidemic.

(Gil Cisneros Twitter Feed, 02/15/2019)

Gil Cisneros had owned up to $1,155,000 in pharmaceutical and biotechnology companies in 2017, according to his House Financial Disclosure form:

• Gil Cisneros had owned up to $1,155,000 in pharmaceutical and biotechnology companies in 2017.

2017 Abbvie 50,000

Alexion 100,000

Allergan 50,000

Amgen 50,000

Biogen 15,000

Bristol-Meyers 100,000

Catalent 15,000

Celgene 250,000

Eli Lilly 15,000

Gilead 50,000

Impax 15,000

Intercept 50,000

Johnson & Johnson 100,000

Merck 50,000

Neurocrine 15,000

Perrigo 15,000

Pfizer 50,000

Regeneron 15,000

Shire 50,000

Vertex 100,000

Total 1,155,000

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure” 11/2/17)

• According to his financial disclosure covering 2017, Gil Cisneros owned between $15,001-$50,000 in AbbVie Pharmaceuticals.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o AbbVie is a biopharmaceutical company. “When we became our own company, AbbVie formed a new kind of enterprise—a biopharmaceutical company. We blend the stability, global scale, resources and commercial capabilities of a pharmaceutical company with the focus and culture of a biotech. Today, our ~30,000 employees around the world focus on delivering transformational medicines and therapies that offer significant patient benefits.” (Our Company, AbbVie, Accessed 03/11/20)

o AbbVie was part of the split from Abbot Laboratories and focused on research-based pharmaceuticals like Humira, Abbot’s blockbuster rheumatoid arthritis drug. “Abbott Laboratories said on Wednesday that it would separate next year into two publicly traded companies, one focused on diagnostics and medical devices like heart stents and the other on what it called “research-based pharmaceuticals,” like Humira, its blockbuster rheumatoid arthritis drug.” (Michael J. De La Merced and Bruce Jaspen, “Abbot Labs to Split Into 2 Companies,” The New York Times, 10/19/11)

• According to his financial disclosure covering 2017, Gil Cisneros owned between $50,001-$100,000 in Alexion Pharmaceuticals.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Alexion Pharmaceuticals has developed medicines. “We’ve delivered transformative medicines for people with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD), generalized Myasthenia Gravis (gMG), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D).” (About Us, Alexion Pharmaceuticals, Accessed 03/11/20)

o Alexion Pharmaceuticals is a global pharmaceutical company.

(Alexion Pharmaceuticals, Google, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$15,001-$50,000 in Allergan PLC.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Allergan PLC is a global pharmaceutical leader developing medicines. “Headquartered in Dublin, Ireland, we are a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.” (About Us, Allergan, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$15,001-$50,000 in Amgen Inc.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Amgen has developed medicines for serious illness.

(Amgen information, Amgen, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned $0 in Astrazeneca.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Editor’s Note: Gil Cisneros did not own Astrazeneca stock in 2017. However, Cisneros previously owned the stock as he disclosed income in the previous year as required.

• According to his financial disclosure covering 2017, Gil Cisneros owned between $1,001-$15,000 in Biogen Inc.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Biogen Inc develops, manufactures, and commercializes therapies focusing on neurology, oncology and immunology. “Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company products address diseases such as multiple sclerosis, non-hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.” (Biogen Inc, Bloomberg.com, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between $0 in Bio-Techne Corp.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Editor’s Note: Gil Cisneros did not own Bio-Techne Corp stock in 2017. However, Cisneros previously owned the stock as he disclosed income in the previous year as required.

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$50,001-$100,000 in Bristol-Myers Squibb.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Bristol-Myers Squibb is a global, biopharmaceutical company.

(About Us, Bristol-Meyers Squibb, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between $1,001-$15,000 in Catalent, Inc.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Catalent, Inc has launched successful pharmaceuticals. “We are a global leader in

providing integrated services, superior delivery technologies and manufacturing solutions to help life science innovators develop and launch successful pharmaceuticals, biologics and consumer health products.” (About Us, Catalent, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$100,001-$250,000 in Celgene Corporation.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Celgene Corporation is a global biopharmaceutical company.

(Celgene, Google, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between $1,001-

$15,000 in Eli Lilly and Company.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Eli Lilly and Company developed medicines. “For more than 140 years, we have

worked tirelessly to develop and deliver trusted medicines that meet real needs. Our growing portfolio of medicines includes treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain fields.” (Current Medicines, Lilly.com, Accessed 03/11/19)

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$15,001-$50,000 in Gilead Sciences Inc.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Gilead developed medicines. “Eli Lilly and Company developed medicines. "For more than 140 years, we have worked tirelessly to develop and deliver trusted medicines that meet real needs. Our growing portfolio of medicines includes treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neurodegeneration, neuroscience, and pain fields."” (How We Operate, Gilead, Access 03/11/19)

o Gilead is a research-based biopharmaceutical company. “Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions.” (Gilead Sciences, Bloomberg.com, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned $1,001-$15,000

in Impax Laboratories.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Impax Laboratories develops and manufactures pharmaceutical products. “Impax Laboratories, LLC develops, manufactures, and markets both proprietary and

multi-source pharmaceutical products utilizing its drug delivery technologies. The Company specializes in the development of niche and controlled release generics, as well as the development of branded products.” (Impax Laboratories, Bloomberg.com, Accessed 03/11/20)

o Impax Laboratories was acquired on May 4, 2018. “On May 4, 2018, Amneal Pharmaceuticals and Impax Laboratories combined under one corporate parent, and now operate as Amneal Pharmaceuticals. Amneal Pharmaceuticals, Inc. is a publicly listed company traded on the New York Stock Exchange (NYSE: AMRX).” (Impax Labs, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$15,001-$50,000 in Intercept Pharmaceuticals.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Intercept Pharmaceuticals manufactures biopharmaceutical products. “Intercept Pharmaceuticals, Inc. manufactures and markets biopharmaceutical products. The Company focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. Intercept Pharmaceuticals serves patients throughout the United States.” (Intercept Pharmaceuticals, Bloomberg.com, 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned $50,001-$100,000 in Johnson & Johnson.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Johnson & Johnson manufactures health care products. “Johnson & Johnson

manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.” (Johnson & Johnson, Bloomberg, Accessed 03/10/20)

o Johnson & Johnson develops products. “We are actively developing treatments for our patients in six important therapeutic areas: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.” (Pharmaceutical Products, Johnson And Johnson, Accessed 03/10/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned $0 in

Medivation Inc.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Editor’s Note: Gil Cisneros did not own Medivation stock in 2017. However, Cisneros previously owned the stock as he disclosed income in the previous year as required.

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$15,001-$50,000 in Merck & Co.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Merck & Co is a global health care company that owns and develops prescription

medications. “Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.” (Merck & Co, Bloomberg.com, Accessed 03/11/20)

o Merk has developed innovative medicines and vaccines. “To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products.” (About, Merck, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between $1,001-

$15,000 in Neurocrine Biosciences Inc.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Neurocrine Biosciences Inc. is a biopharmaceutical company that has developed

treatments. “Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson’s disease, congenital adrenal hyperplasia and uterine fibroids*.” (About, Neurocrine Biosciences Inc, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned $0 in Novo

Nordisk.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Editor’s Note: Gil Cisneros did not own Novo Nordisk stock in 2017. However, Cisneros previously owned the stock as he disclosed income in the previous year as required.

• According to his financial disclosure covering 2017, Gil Cisneros owned between $1,001-

$15,000 in Perrigo Company.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Perrigo Company develops, manufactures, and distributes generic prescription

pharmaceuticals. “Perrigo Company PLC is a global healthcare supplier that develops, manufactures, and distributes OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The Company's primary markets and locations of manufacturing and logistics operations are the US, UK, Mexico, and Australia.” (Perrigo Co PLC, Bloomberg.com, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$15,000-$50,000 in Pfizer, Inc.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Pfizer, Inc. operates as a pharmaceutical company. “Pfizer Inc. operates as a

pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.” (Pfizer, Bloomberg.com, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between $1,001-

$15,000 in Regeneron Pharmaceuticals, Inc.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Regeneron Pharmaceuticals, Inc is a biotechnology company that develops

medicines. “Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.” (About, Regeneron Pharmaceuticals, Accessed 03/11/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$15,001-$50,000 in Shire PLC.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Shire PLC is a global biotechnology group focused on developing rare disease

therapies. “SHIRE PLC is a global biotechnology group focused on serving people with rare diseases and other specialized conditions. The Company develops products across core therapeutic areas including hematology, immunology, neuroscience, ophthalmics, lysosomal storage disorders, gastrointestinal, internal

medicine endocrine and hereditary angioedema, and in oncology.” (Shire PLC, Bloomberg.com, Accessed 03/10/20)

• According to his financial disclosure covering 2017, Gil Cisneros owned between

$50,001-$100,000 in Vertex Pharmaceuticals.

(Clerk Of The House Of Representatives, “Gil Cisneros 2017 Financial Disclosure”, 11/2/17)

o Vertex Pharmaceuticals is a global biotechnology company. “Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.” (Who We Are, Vertex Pharmaceuticals, Accessed 03/11/20)

Gil Cisneros has owned up to $635,000 in pharmaceutical and biotechnology companies in 2018, according to his 2019 House Financial Disclosure form:

• Gil Cisneros invested up to $635,000 in pharmaceutical and biotechnology companies in 2018.

2018 Bristol-Myers Squibb 50,000

Catalent 15,000

Acadia Pharma 15,000

AbbVie 50,000

Alexion 50,000

Allergan 15,000

Amgen 15,000

Amneal 15,000

Biogen 15,000

Celgene 15,000

Eli Lilly 15,000

Gilead 15,000

Johnson & Johnson 50,000

Merk & Co 50,000

Neurocrine 50,000

Pfizer 50,000

Procter 50,000

Vertex 100,000

Total 635,000 (Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his financial disclosure covering 2018, Gil Cisneros owned $15,001-$50,000 in Bristol-Myers Squibb.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $1,001-$15,000 in Catalent Inc.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $1,001-$15,000 in Acadia Pharmaceuticals.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $15,001-$50,000 in AbbVie Pharmaceuticals.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $15,001-$50,000 in Alexion Pharmaceuticals.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between

$1,001-$15,000 in Allergan PLC.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $1,001-$15,000 in Amgen Inc.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $1,001-$15,000 in Amneal Pharmaceuticals Inc.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $1,001-$15,000 in Biogen Inc.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between

$1,001-$15,000 in Celgene Corp.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $1,001-$15,000 in Eli Lilly and Company.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $1,001-$15,000 in Gilead Sciences, Inc.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between

$15,001-$50,000 in Johnson & Johnson.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between

$15,001-$50,000 in Merck & Co.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $15,001-$50,000 in Neurocrine Biosciences, Inc.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between

$15,001-$50,000 in Pfizer, Inc.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $15,001-$50,000 in Procter & Gamble Company.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

• According to his latest financial disclosure covering 2018, Gil Cisneros owned between $50,001-$100,000 in Vertex Pharmaceuticals.

(Clerk of The House Of Representatives, “Gil Cisneros 2018 Financial Disclosure, 08/13/19)

The Gilbert and Jackie Cisneros Foundation owned stock in Horizon Pharma PLC:

Editor’s Note: The Gilbert and Jackie Cisneros Foundation were invested in the pharmaceutical company while the company hiked prices between 2015 and 2016. The foundation was not invested in the pharma company after 2016.

• In 2015, The Gil and Jackie Cisneros Foundation owned shares in Horizon Pharma PLC worth $6,287.

(Gilbert And Jackie Cisneros Foundation 990, ProPublica, 11/15/2016)

• In 2016, The Gil and Jackie Cisneros Foundation owned shares in Horizon Pharma PLC worth $5,155.

(Gilbert And Jackie Cisneros Foundation 990, ProPublica, 11/10/2017)

o Between January of 2014 to July of 2016, Horizon increased the list price for Vimovo six times, raising the price to $2,250. “And Horizon has since boosted the price six more times; it’s now at $2,250.” (Ed Silverman, “Pharma trade group says price gougers are outliers, but then accepts two more,” Stat News, 07/26/16)

Since 2014, Horizon has increased prices for the pill by more than 1,600%:

• Beginning in 2014, Vimovo’s price increased by 1,600%. “Package list price increases for the combination drugs, Duexis and Vimovo over the years, despite no change in the formulations of the drugs. Beginning in 2014, the two drugs have had the same periodic jumps -a more than 1,600 percent increase -over time.”

(WRCBtv, “Combination drug prices rise as much as 1,600%,” NBC News, 11/30/19)

Horizon Pharma raised the price of a medication called Vimovo from $138 in 2014 to $2,797 in 2018:

• In November of 2013, Horizon announced the acquisition of Vimovo from AstraZeneca for $35 million.

(J. Kule Bass, “How a cheap generic pain reliever and a cheap generic acid inhibitor are combined to become an expensive prescription

drug,” Harvest.com, 05/22/15)

• In January of 2014 on the first day Horizon sold Vimovo, the company increased the price for 60 tables from $137.60 to $959.04, an increase of $597%.

(J. Kule Bass, “How a cheap generic pain reliever and a cheap generic acid inhibitor are combined to become an expensive prescription

drug,” Harvest.com, 05/22/15)

• In August of 2014, Horizon increased the list price for Vimovo by 9.9%.

(J. Kule Bass, “How a cheap generic pain reliever and a cheap generic acid inhibitor are combined to become an expensive prescription

drug,” Harvest.com, 05/22/15)

• In September of 2014, Horizon increased the list price for Vimovo by 17.2%

(J. Kule Bass, “How a cheap generic pain reliever and a cheap generic acid inhibitor are combined to become an expensive prescription

drug,” Harvest.com, 05/22/15)

• One year after the January 1, 2014 price hike, Horizon again hiked the price to $1,678.32 in January of 2015. “By January 1, 2014, Horizon had increased the price of Vimovo by 594% to nearly $1,000 per 60-tablet bottle. One year later, Horizon again hiked the price, this time to $1,678.32.” (Nicole Grave, “Federal investigation probing Horizon Pharma’s patient assistance program,” BioPharma Dive, 03/02/16)

• In January of 2015, Horizon increased the list price for Vimovo by 35.8%

(J. Kule Bass, “How a cheap generic pain reliever and a cheap generic acid inhibitor are combined to become an expensive prescription

drug,” Harvest.com, 05/22/15)

• This is the same tactic for which Valent and Turing were criticized. “In late 2013, the company bought the Vimovo pain reliever from AstraZeneca and, in January 2014, on the first day it could sell the pill, Horizon raised the list price for 60 tablets to $959, a 597 percent increase from $127, according to Truven Health Analytics. This is the same tactic for which Valeant and Turing were criticized.” (Ed Silverman, “Pharma trade group says price gougers are

outliers, but then accepts two more,” Stat News, 07/26/16)

• Horizon Pharma PLC raised the prices on their painkiller Vimovo in 2018. “Irish drugmaker has jacked up the price of a painkiller to nearly $3,000 a bottle. The drug is 22 times more expensive than when the company acquired it in late 2013.” (Matt Egan, “Painkiller that once cost $138 is now $2,979,” CNN, 02/15/2018)

• The day after President Trump’s State Of The Union in which he vowed to lower drug costs, Horizon Pharma raised the prices of Vimovo by 9.9% to $2,979 in January of 2018. “The day after Trump's speech, Horizon (HZNP) raised the average wholesale price on Vimovo by 9.9% to $2,979 per bottle. Horizon confirmed to CNNMoney the price increase, which was first reported by the Financial Times.” (Matt Egan, “Painkiller that once cost $138 is

now $2,979,” CNN, 02/15/2018)

• Horizon PLC is a global biopharmaceutical company.

(Company, Horizon, Accessed 03/11/20)

• Vimovo is an anti-inflammatory drug that is used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in adults.

(Vimovo, Accessed 03/11/20)

The Gilbert and Jackie Cisneros Foundation owned stock in Sanofi-Aventis:

• In 2017, The Gilbert and Jackie Cisneros Foundation owned shares in Sanofi-Aventis Sponsored ADR worth $7,632.

(Gilbert And Jackie Cisneros Foundation 990, ProPublica, 2017)

Sanofi-Aventis, a foreign pharmaceutical company, increased the price of its insulin from $35 when it was introduced in 2001 to $270 in 2019:

• Sanofi’s insulin brand Lantus was $35 a vial when it was introduced in 2001 but was raised to $270 in 2019. “According to IBM Watson Health data, Sanofi’s popular insulin brand Lantus was $35 a vial when it was introduced in 2001; it’s now $270.” (Tiffany Stanley, “Life, Death, and Insulin,” The Washington Post, 01/07/19)

o Editor’s Note: 671.43% = ((270 -35)/35)*100

• The soaring prices of insulin has provoked a bipartisan concern. “In Washington, the soaring price of insulin has provoked bipartisan concern. Members of Congress are trying to parse the factors that have caused the spike.” (Tiffany Stanley, “Life, Death, and Insulin,” The Washington

Post, 01/07/19)

• Sanofi-Aventis is a French pharmaceutical company. “Sanofi-Aventis, French pharmaceutical company founded in 2004 through the merger of Sanofi-Synthelabo SA and an much larger firm, Aventis.” (Sanofi-Aventis, Encyclopedia Britannica, Editors, Accessed 02/12/20)

• Sanofi-Aventis’s global headquarters is in France, according to the Sanofi website.

(About, Sanofi, Accessed 02/12/20)

• The soaring prices of insulin has provoked a bipartisan concern. “In Washington, the

soaring price of insulin has provoked bipartisan concern. Members of Congress are trying to parse the factors that have caused the spike.” (Tiffany Stanley, “Life, Death, and Insulin,” The Washington

Post, 01/07/19)